Prosecution Insights
Last updated: November 21, 2026

Kyle A Purdy, USPTO Patent Examiner

Listed by the USPTO as PURDY, KYLE A

Tech Center 1600 • Art Units: 1611

This examiner grants 41% of resolved cases

Analysis

PURDY, KYLE A is assigned to tech center 1600 and art unit 1611. His profile includes 1004 resolved cases, a 40.8% allowance rate, a 35.8% interview lift, and a median of 1519 days to allowance.

The listed companies are Textile-Based Delivery Inc., University of Florida Research Foundation Inc., and The Brigham and Women's Hospital Inc. Listed firms include NEO IP, CANTOR COLBURN LLP - UPL LIMITED, and Abel Schillinger, LLP. The allowance rate is below half, while the positive interview lift supports preparing interviews as part of a broader strategy for addressing examination issues.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

40.8%
Allow Rate
-19.2% vs TC avg
1,094
Total Applications
+35.8%
Interview Lift
1519
Avg Prosecution Days
Based on 1004 resolved cases, 2023–2026

Rejection Statute Breakdown

1.4%
§101 Eligibility
13.8%
§102 Novelty
62.8%
§103 Obviousness
14.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17630843 SYNERGISTIC MIXTURES FOR ARTHROPOD TOXICITY AND REPELLENCY Final Rejection University of Florida Research Foundation, Incorporated
18272024 LIPID NANOPARTICLES FOR TARGETED DELIVERY OF MRNA Non-Final OA The Brigham and Women's Hospital, Inc.
18667002 SKIN CARE SERUM COMPOSITION WITH NATURAL POLYMERS Final Rejection The Procter & Gamble Company
18821462 POLYANION COATED LIPID NANOPARTICLES AND METHODS OF USE THEREOF Final Rejection Massachusetts Institute of Technology
18703637 IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER Non-Final OA Ohio State Innovation Foundation
18679898 PURIFIED EXOSOME PRODUCTS, METHOD OF MAKING, AND METHODS OF USING Non-Final OA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
18700612 PLANT DISEASE RESISTANCE INDUCING METHOD, PLANT DISEASE RESISTANCE INDUCING DEVICE, AND PLANT DISEASE RESISTANCE INDUCING AGENT Final Rejection TOHOKU UNIVERSITY
18953835 ORAL PRODUCTS, THREE-DIMENSIONAL PRINTERS USED FOR FORMING ORAL PRODUCTS, AND THREE-DIMENSIONAL PRINTING METHODS FOR FORMING ORAL PRODUCTS Non-Final OA Altria Client Services LLC
17422859 ANTIBACTERIAL COMPOSITION Non-Final OA LG CHEM, LTD.
18706889 METHODS AND SYSTEMS FOR POINT-OF-CARE SYNTHESIS AND ADMINISTRATION OF PARTICLE-BASED THERAPEUTICS Final Rejection Verily Life Sciences LLC
18256655 EXTRACT OF AT LEAST ONE PLANT OF THE CROCUS SATIVUS SPECIES COMPRISING A HIGH CONTENT OF CROCINS AND A LOW CONTENT OF SAFRANAL, AND COSMETIC USE THEREOF AS ANTIOXIDANT Final Rejection L'OREAL
18437576 COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF Non-Final OA Mitsubishi Chemical Corporation
17767783 COMPOSITIONS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO CELLS Final Rejection University of Maryland, Baltimore
18867060 CONCENTRATED CONDITIONING COMPOSITIONS Final Rejection Conopco, Inc., d/b/a UNILEVER
18723765 LIQUID COMPOSITION HAVING ENHANCED ANTIMICROBIAL ACTIVITY Non-Final OA Conopco Inc., d/b/a UNILEVER
17723155 SUSTAINED-RELEASE MICROPARTICLES FOR SUSTAINED RELEASE OF DRUG Non-Final OA INVENTAGE LAB INC.
15551596 COSMETIC PRODUCT COMPRISING A METAL CAN, AND THE CONTENTS OF SAME Final Rejection BEIERSDORF AG
19104621 COMPOSITION OF LIPID NANOPARTICLES Non-Final OA SUZHOU ABOGEN BIOSCIENCES CO., LTD.
19001161 COSMETIC COMPOSITIONS COMPRISING A CYCLODEXTRIN HAVING A PARTICLE SIZE DISTRIBUTION Non-Final OA ROQUETTE FRERES
18832510 A Composition Against Osmotic Stress Non-Final OA ELC Management LLC
18877427 HERBICIDAL COMBINATIONS AND A METHOD FOR CONTROLLING UNDESIRED VEGETATION Non-Final OA UPL Europe Ltd.
18252656 Base Sheet with Surface Fiber Structure Final Rejection Alejandra ZAPATA ARANGO

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kyle A Purdy's allowance rate?

40.8% of resolved applications examined by Kyle A Purdy were allowed (1,004 resolved cases), compared with 35.4% across Art Unit 1611 over the last five years.

Does an interview help with examiner Kyle A Purdy?

This examiner's interview lift is +35.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kyle A Purdy take to allow a patent?

Applications allowed by Kyle A Purdy took 1,519 days on average from filing to allowance.

Which art unit does examiner Kyle A Purdy work in?

Kyle A Purdy examines applications in Art Unit 1611 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month